Evidence map›Paper›PMID 40874220›Full record

ArticleFrontiers in oncology2025

Case Report: Breast ductal carcinoma

Sibei Ruan, Jian Zhou, Rui Tang, Tao Wang, Xia Gao, Lixian Mou, Mingxi Tang

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sibei Ruan *Department of Pathology, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, China.
Jian Zhou *Department of Pathology, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, China.
Rui Tang *Department of Pathology, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, China.
Tao WangDepartment of Pathology, The Yaan People's Hospital (Yaan Hospital of West China Hospital, Sichuan University), Yaan, Sichuan, China.
Xia GaoDepartment of Pathology, The Yaan People's Hospital (Yaan Hospital of West China Hospital, Sichuan University), Yaan, Sichuan, China.
Lixian MouDepartment of Nuclear Medicine, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, China.
Mingxi TangDepartment of Pathology, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Numerous studies have reported considerable heterogeneity in breast ductal carcinoma Case presentation: In this work, we report a case of rapidly progressing multiple metastases in a patient with DCIS-MI following conventional treatment. Subsequent fluorescence Conclusion: This case suggests that even patients with microinvasive lesions who are HER2-positive may exhibit unexpected stability under targeted therapy, warranting close surveillance in such cases.

Indexed as

breast cancerHER2 genemetastasismicroinvasiontherapy

Identifiers

PMID40874220
PMCPMC12378505

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.